ApicHope(SZ:300723) Ge Long Hui·2025-09-19 03:55Core Viewpoint - The company has received approval from the National Medical Products Administration for the addition of a 45mg specification of Oseltamivir Phosphate capsules, expanding its product offerings in the antiviral market [1][2]. Company Summary - The company's wholly-owned subsidiary, Guangzhou Yipinhong Pharmaceutical Co., Ltd., has been granted a drug supplement application approval for Oseltamivir Phosphate capsules, allowing for a new 45mg specification alongside the existing 75mg [1]. - The approved indications for Oseltamivir Phosphate capsules include treatment for influenza A and B in adults and children aged one year and older, with a recommendation for use within 48 hours of symptom onset [1]. - The company has made changes to the excipient quantities, packaging materials, and registration standards as part of the approval process, with a validity period of 12 months for the new production process and quality standards [1]. Industry Summary - Oseltamivir Phosphate is a neuraminidase inhibitor recommended by the World Health Organization (WHO) and is a first-line antiviral drug for influenza as per the 2025 edition of the Influenza Diagnosis and Treatment Plan [2]. - The drug is classified as a Category B product under the national medical insurance scheme and is included in the 2018 version of the essential drug list in China [2]. - According to data from Minet, the sales revenue of Oseltamivir in Chinese urban public hospitals and county-level public hospitals is projected to be approximately 322.571 million RMB in 2024 [2].